GSK rejects idea of buying AstraZeneca
LONDON May 3 (Reuters) - Britain's biggest drugmaker GlaxoSmithKline has no interest in buying its smaller British rival AstraZeneca, GSK's chief executive said on Thursday.
AstraZeneca's future is in flux, following the planned early exit of its CEO David Brennan from June 1, leading some analysts to speculate it might become a takeover target.
GSK CEO Andrew Witty, however, told shareholders at the company's AGM that buying a big company like AstraZeneca would be "very distracting".
- Canada's parliament attacked, soldier fatally shot nearby |
- NOAA employee charged with stealing U.S. dam information
- Sweden gets two new sightings, as hunt for undersea intruder goes on
- Canada probes Michael Zehaf-Bibeau as possible suspect in Ottawa shooting: source
- Special Report: Traffickers use abductions, prison ships to feed Asian slave trade